Total Funding
8
Total FundingSeed raised
Growth Score
pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
467978
Aptalis Pharma develops and markets therapies for the treatment of gastrointestinal diseases and disorders.
David W. Mims: Executive Vice President and COOPast Role: Eurand, President, US Specialty Pharmaceuticals
About the Company
Aptalis Pharma (known as Axcan Pharma until May 2011) is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic
insufficiency. Aptalis hopes to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers.
Aptalis was acquired by TPG Capital in 2008, and it acquired Eurand in 2010. It changed its name from Axcan Pharma to Aptalis in May 2011.
